ActRII Antagonist Therapy for Ocular Vascular Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular disorders associated with ischemia and microvascular insufficiency, such as diabetic retinopathy, have limited efficacy and are often accompanied by adverse complications, necessitating the development of more effective therapies to improve vision and manage vascular disorders of the eye.
Innovation Solution
A composition comprising an ActRII antagonist polypeptide, specifically a polypeptide with an amino acid sequence at least 90% identical to SEQ ID NO: 1, is used to treat or prevent vascular disorders of the eye, improving vision by inhibiting ActRII-mediated signaling, which can be administered alone or in combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (laser photocoagulation, low dose radiation, surgery) are used to treat vascular disorders of the eye, then vascular and nerve damage can be ameliorated, but the treatments have limited or short lasting effects and are associated with high recurrence rates and adverse complications
Solution Approach 1:
The patent changes the biochemical parameter by introducing a novel ActRII antagonist mechanism of action, which blocks activin signaling pathways to inhibit neovascularization. This represents a fundamental shift from physical destruction methods (laser, radiation, surgery) to a targeted molecular therapy that addresses the underlying pathophysiology, thereby improving durability of treatment effect while reducing adverse complications
Solution Approach 2:
The ActRII antagonist serves as a molecular intermediary that mediates the therapeutic effect by selectively blocking activin type II receptors. This intermediary approach allows for targeted inhibition of pathological neovascularization while sparing normal physiological processes, thus improving treatment reliability and reducing harmful side effects compared to non-specific destructive therapies
2Reliability
If laser photocoagulation therapy is applied to treat neovascular membranes, then initial response is achieved, but recurrence rates are high and vision loss risk increases due to treatment damage
Solution Approach 1:
The patent converts the harmful uncontrolled neovascularization process into a beneficial therapeutic target by using ActRII antagonists to selectively inhibit the pathological blood vessel growth. This approach transforms the disease mechanism itself into the point of intervention, achieving sustained efficacy while avoiding the vision loss damage caused by laser photocoagulation
Solution Approach 2:
The patent replaces the mechanical/physical destruction mechanism of laser photocoagulation with a biochemical mechanism involving ActRII antagonist binding to activin receptors. This substitution eliminates the thermal damage and scarring associated with laser treatment while maintaining therapeutic efficacy through targeted molecular inhibition of neovascularization
3Reliability
If low dose radiation therapy is used to treat neovascularization, then treatment effect is achieved, but recurrence rate remains high
Solution Approach 1:
The ActRII antagonist is administered before neovascularization can progress to cause significant damage or recur after previous treatments. By blocking activin signaling pathways in advance, the therapy prevents the formation of new blood vessels that would otherwise lead to disease recurrence, thereby extending the duration of therapeutic effect and improving long-term outcomes
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye. The compositions of the invention comprise ACTRII antagonists.